The reduction in price target by Oppenheimer suggests that while the firm still believes BioVie has an outperforming potential, there may be factors that have led to a more conservative valuation of the company's stock. This could be due to revised expectations for the company's financial performance, market conditions, or other company-specific factors. The significant decrease in the price target is likely to be viewed negatively by the market in the short term, potentially leading to a decrease in BioVie's stock price.